Clinical Trials Logo

Filter by:
NCT ID: NCT06041620 Recruiting - Thalassemia Major Clinical Trials

Safety and Efficacy Evaluation of Autologous CRISPR-Cas12b Edited Hematopoietic Stem Cells

Start date: August 31, 2023
Phase: N/A
Study type: Interventional

This is a single-arm, open, single-injection exploratory clinical study with two transfusion-dependent β thalassemia (β-TDT) participants planned to enroll.

NCT ID: NCT06041542 Completed - 10-second G&R Test Clinical Trials

Evaluation of the Screening Effect of Artificial Intelligence Hand Activity Evaluation System for Cervical Spondylosis

Start date: December 1, 2020
Phase:
Study type: Observational

The purpose of this study: 1. Build an artificial intelligence screening tool for cervical spondylosis based on hand function analysis; 2. Verify the accuracy of cervical spondylosis screening tools.

NCT ID: NCT06041490 Not yet recruiting - Clinical trials for Liver Transplant; Complications

Adjuvant Therapy for High-risk Hepatocellular Carcinoma Post Liver Transplantation

Start date: September 2023
Phase: Phase 2
Study type: Interventional

1. Explore the impact of postoperative administration of multi-kinase inhibitors (including sorafenib, lenvatinib, and regorafenib) in conjunction with bevacizumab on post-transplant recurrence, overall survival, and drug safety in liver transplant recipients at high risk of recurrence in hepatocellular carcinoma. 2. The primary objective of this study is to evaluate the efficacy of multi-kinase inhibitors in combination with bevacizumab as adjuvant therapy in liver transplant recipients with hepatocellular carcinoma who present high-risk factors for recurrence, based on the one-year recurrence-free survival rate (1-year RFS rate). 3. The secondary objectives of this study are to assess the effectiveness and safety of multi-kinase inhibitors in combination with bevacizumab as adjuvant therapy in liver transplant recipients with hepatocellular carcinoma who present high-risk factors for recurrence, based on the following parameters: Recurrence-free survival (RFS) duration, Overall survival (OS), Two-year and three-year RFS rates, Graft survival, Quality of life evaluation (QoL), Incidence of adverse events and serious adverse events.

NCT ID: NCT06041477 Recruiting - Clinical trials for Hepatocellular Carcinoma

Concurrently vs Sequentially Combined HAIC With Targeted and Immunotherapy in Potentially Resectable HCC

HAIC
Start date: September 2023
Phase: Phase 3
Study type: Interventional

The goal of this clinical trial is to compare HAIC concurrently with sequentially combined with targeted and immunotherapies in terms of efficacy and safety in patients with potentially resectable intermediate and advanced HCC (CNLC stage IIa~IIIa). The main questions it aims to answer are: - Does a "strong combination" regimen of three simultaneous treatments (HAIC, targeted agents and immunotherapy) definitely result in a higher surgical conversion rate and better survival benefit? - Can the combination of targeted and immunotherapies based on patients' response to HAIC therapy avoid over-treatment of some patients without affecting the surgical conversion rate and overall survival? Participants will be randomly assigned to receive either HAIC concurrently or sequentially combined with targeted and immunotherapies. Researchers will compare concurrent treatment group with sequential treatment group to see if there are different in terms of the conversion resection rate, long-term survival, and safety.

NCT ID: NCT06041451 Recruiting - Clinical trials for Guillain-Barre Syndrome

Early and Late Prognosis in Patients With Guillain-Barre Syndrome

Start date: January 2, 2013
Phase: Phase 4
Study type: Interventional

The goal of this observational study is to explore significant indicators to predict the early prognosis and late prognosis in patients with Guillain-Barre syndrome.

NCT ID: NCT06041425 Completed - Pain Clinical Trials

The Effects of Oxycodone Versus Sufentanil on Pain and Inflammatory Response After TACE

Start date: August 7, 2023
Phase: Phase 4
Study type: Interventional

The purpose of this randomized, double-blind trial was to compare the effects of preemptive Oxycodone and sufentanil at the same dose on pain and inflammatory response after transcatheter arterial chemoembolization (TACE) of hepatocellular carcinoma. To study the effect of single dose intravenous injection of Oxycodone and sufentanil before TACE on inflammatory reaction after TACE; And (ii) evaluate the effects of different opioid drugs on pain and nausea/vomiting after TACE.

NCT ID: NCT06041412 Recruiting - Clinical trials for Diabetic Peripheral Neuropathy

The Effect of Related Blood Markers on Diabetic Peripheral Neuropathy

Start date: February 1, 2012
Phase:
Study type: Observational

The goal of this observational study is to explore the relationship between related blood indicators and diabetic peripheral neuropathy(DPN).

NCT ID: NCT06041399 Recruiting - Clinical trials for Diabetic Peripheral Neuropathy

The Effect of Related Blood Markers on Diabetic Peripheral Neuropathy

Start date: February 1, 2012
Phase: Phase 4
Study type: Interventional

The goal of this observational study is to explore the relationship between related blood indicators and diabetic peripheral neuropathy.

NCT ID: NCT06041282 Recruiting - Adhesive Capsulitis Clinical Trials

Conservative Treatment of Early Adhesive Capsulitis

Start date: October 30, 2023
Phase: N/A
Study type: Interventional

A prospective, multicentre, randomized controlled study comparing the efficacy of conservative treatment for early adhesive capsulitis

NCT ID: NCT06041217 Recruiting - Obesity Clinical Trials

A Research Study to See How Well Semaglutide Helps People Who Have a Body Weight Above the Healthy Weight Range

STEP12
Start date: September 15, 2023
Phase: Phase 3
Study type: Interventional

This study will look at how the investigational dose of semaglutide works in helping people with excess body weight, to lose weight. This study will compare the weight loss in people taking semaglutide to people taking "dummy" medicine (placebo). The study will last for about 1 year. The participants will have 12 visits at the clinic and 3 remote visits by phone calls with the study doctor or staff.